| 18.15 -1.8 (-9.02%) | 03-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 25.44 | 1-year : | 32 |
| Resists | First : | 21.78 | Second : | 27.39 |
| Pivot price | 21.38 |
|||
| Supports | First : | 12.69 | Second : | 10.56 |
| MAs | MA(5) : | 20.62 |
MA(20) : | 20.03 |
| MA(100) : | 11.74 |
MA(250) : | 13.02 |
|
| MACD | MACD : | 1.8 |
Signal : | 2.5 |
| %K %D | K(14,3) : | 32.9 |
D(3) : | 44.2 |
| RSI | RSI(14): 46.1 |
|||
| 52-week | High : | 39.75 | Low : | 6.26 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PMN ] has closed above bottom band by 15.0%. Bollinger Bands are 114.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 21.05 - 21.19 | 21.19 - 21.31 |
| Low: | 16.48 - 16.65 | 16.65 - 16.77 |
| Close: | 17.38 - 17.6 | 17.6 - 17.78 |
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Fri, 06 Mar 2026
Eugene Williams Increases Stake in ProMIS Neurosciences Inc with Recent Share Purchase - GuruFocus
Wed, 04 Mar 2026
Eugene Williams Increases Stake in ProMIS Neurosciences Inc - GuruFocus
Wed, 04 Mar 2026
Promis Neurosciences (NASDAQ:PMN) Director Eugene Williams Buys 2,000 Shares - MarketBeat
Fri, 27 Feb 2026
PMN Stock Price and Chart — NASDAQ:PMN - TradingView
Fri, 30 Jan 2026
ProMIS lines up up to $175M to extend runway into 2028, fund Alzheimer’s trial - Stock Titan
Sat, 06 Dec 2025
ProMIS Neurosciences (PMN) Price Target Increased by 2,288.89% to 137.06 - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 24.9 (%) |
| Held by Institutions | 135.8 (%) |
| Shares Short | 128 (K) |
| Shares Short P.Month | 19 (K) |
| EPS | -20 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.26 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -85.4 % |
| Return on Equity (ttm) | -355.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -13.19 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -28 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -0.89 |
| PEG Ratio | 0 |
| Price to Book value | 4.12 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|